Cybin Funding: How Much Did They Raise & Key Investors

How Much Did Cybin Raise?
Funding & Key Investors

Cybin has solidified its position within the competitive biotechnology landscape, securing a total capital infusion of $80M. This trajectory of financial backing, highlighted by a recent strategic investment of $50M, underscores the market confidence in the firm's specialized approach to mental health treatment. By leveraging these resources, the company continues to bridge the gap between academic research and scalable clinical applications, ensuring that its proprietary drug discovery platforms remain at the forefront of the industry.

The firm's ability to attract significant financing reflects its operational maturity and the increasing institutional interest in psychedelic-derived therapeutics. As the company navigates the complexities of international regulatory environments across North America and Europe, this latest injection of capital serves as a critical catalyst for its ongoing development programs.

What is Cybin?

Cybin

Business Services

Research & Development

Cybin operates as a premier biotechnology entity dedicated to the advancement of psychedelic-based therapeutics. Founded in 2019 and headquartered in Canada, the organization maintains a robust international footprint, spanning the United States, the United Kingdom, the Netherlands, and Ireland. The company distinguishes itself through a multi-faceted approach that integrates proprietary drug discovery platforms with innovative delivery systems and novel formulation techniques. By collaborating with a global network of scientists and clinical partners, Cybin aims to address the systemic gaps in current mental health care, moving beyond traditional pharmaceutical models to offer more effective, patient-centric treatment regimens.

How much funding has Cybin raised?

Cybin has raised a total of $80M across 2 funding rounds:

2023

Share Placement

$30M

2025

Debt

$50M

Share Placement (2023): $30M, investors not publicly disclosed

Debt (2025): $50M, investors not publicly disclosed

Key Investors in Cybin

Undisclosed Investor

An undisclosed institutional partner providing strategic capital to support the firm's long-term research and development objectives.

Undisclosed Investor

A private equity participant focused on high-growth biotechnology ventures and innovative therapeutic platforms.

Undisclosed Investor

A specialized investment group providing debt financing to facilitate the scaling of clinical-stage pharmaceutical operations.

What's next for Cybin?

With the recent infusion of capital, Cybin is well-positioned to accelerate its clinical pipeline and refine its drug delivery infrastructure. The strategic focus will likely shift toward scaling its proprietary platforms to meet the rigorous demands of late-stage clinical trials and eventual commercialization. As the company continues to navigate the regulatory landscape, the emphasis will remain on validating its novel formulations and treatment protocols. Investors and stakeholders should anticipate a period of intensified research output and potential expansion of its international clinical network, as the firm seeks to solidify its leadership in the emerging field of psychedelic medicine.

See full Cybin company page

See More Financial Insights